Vetr Inc. Lowers Juno Therapeutics, Inc. (NASDAQ:JUNO) to Sell
Juno Therapeutics, Inc. (NASDAQ:JUNO) was downgraded by investment analysts at Vetr from a “hold” rating to a “sell” rating in a note issued to investors on Monday. They presently have a $28.47 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective indicates a potential downside of 1.49% from the company’s current price.
JUNO has been the topic of a number of other reports. Leerink Swann restated an “outperform” rating on shares of Juno Therapeutics in a report on Monday, June 12th. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Tuesday, July 11th. BidaskClub lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. BTIG Research lowered Juno Therapeutics from a “neutral” rating to a “sell” rating and boosted their price target for the company from $22.60 to $23.73 in a report on Thursday, June 8th. Finally, Wedbush restated a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $30.86.
Juno Therapeutics (NASDAQ JUNO) opened at 28.90 on Monday. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04. The firm has a 50-day moving average price of $28.51 and a 200 day moving average price of $24.26. The firm’s market capitalization is $3.01 billion.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.64) earnings per share. On average, equities analysts forecast that Juno Therapeutics will post ($3.05) EPS for the current year.
In related news, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,041,500 shares of company stock worth $217,230,360. 15.26% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. M&T Bank Corp bought a new stake in Juno Therapeutics during the first quarter worth about $381,000. Norges Bank bought a new stake in Juno Therapeutics during the fourth quarter worth about $13,993,000. Nisa Investment Advisors LLC bought a new stake in Juno Therapeutics during the first quarter worth about $200,000. Laurion Capital Management LP bought a new stake in Juno Therapeutics during the first quarter worth about $390,000. Finally, BB Biotech AG increased its stake in Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock worth $48,485,000 after buying an additional 315,000 shares in the last quarter. 64.60% of the stock is currently owned by institutional investors and hedge funds.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.